INCB099280, an oral PD-L1 inhibitor, dropped in Part 1 as Incyte cut its checkpoint pipeline

What was tried

Incyte ran a Phase 1/2 study of the oral small-molecule PD-L1 inhibitor INCB099280 combined with the VEGFR tyrosine kinase inhibitor axitinib in adults with advanced solid tumors (ClinicalTrials.gov, NCT05949632). Part 1 was a dose-finding stage that combined INCB099280 at 400 mg twice daily with axitinib at 5 mg twice daily, and Part 2 was planned to assess antitumor activity (ClinicalTrials.gov, NCT05949632). The study opened on 2024-04-16 and was restricted to sites in the United Kingdom and the European Union (ClinicalTrials.gov, NCT05949632). It reached an actual enrollment of 5 participants before closing, with a primary completion date of 2025-06-06 (ClinicalTrials.gov, NCT05949632). The posted reason for stopping was "This was a strategic business decision. There were no safety concerns contributing to this decision" (ClinicalTrials.gov, NCT05949632).

The biological hypothesis

PD-L1, encoded by CD274, is one of the most clinically validated targets in oncology. In Open Targets its association with neoplasm reaches an overall score of 0.5955, anchored by a clinical evidence score of 0.9295 and a literature score of 0.9997 (Open Targets Platform, CD274 ENSG00000120217, EFO_0000616). Approved PD-1 and PD-L1 antibodies established the axis, and the open question INCB099280 was built to answer is whether a small molecule can reproduce antibody-level blockade with oral dosing. Incyte's earlier oral PD-L1 inhibitor INCB086550 was characterized as a potent compound that blocks the PD-1 and PD-L1 interaction and drives PD-L1 dimerization and internalization, a mechanism distinct from antibody occupancy (Cancer Discovery, Koblish et al., 2022). Other groups reported the same internalization and degradation behavior for small-molecule PD-L1 binders (J Med Chem, Wang et al., 2022) and again in later work (J Med Chem, Sun et al., 2023), while CCX559 showed oral antitumor activity in models (PLoS One, Sullivan et al., 2023). Adding axitinib brought a VEGFR angle intended to complement checkpoint blockade in tumors such as renal cell carcinoma.

What actually happened

Only Part 1 ran. Among the 5 dosed participants, the objective response rate was 20.0 percent and the disease control rate was 80.0 percent, with one dose-limiting toxicity recorded and all 5 participants experiencing a treatment-emergent adverse event (ClinicalTrials.gov, NCT05949632). The single responder had a duration of response of 8.0 months (ClinicalTrials.gov, NCT05949632). Pharmacokinetic samples were collected but not analyzed because the cohort was too small, as pre-specified in the statistical analysis plan (ClinicalTrials.gov, NCT05949632). Enrollment closed during Part 1 and Part 2 was never conducted, after Incyte decided to discontinue the INCB099280 program for strategic reasons with no safety concerns contributing (ClinicalTrials.gov, NCT05949632). The decision was part of a broader pipeline cull in which Incyte dropped both of its oral PD-L1 inhibitors and refocused on programs it judged higher impact (FierceBiotech, 2025, and BioPharma Dive, 2025). A planned combination of INCB099280 with the KRAS G12C inhibitor adagrasib was also shelved as part of the same review (ApexOnco, 2025). The drug had no openFDA FAERS reports, consistent with an investigational oral small molecule (openFDA FAERS, queried 2026-06-06).

Failure mechanism, best guess

This was a portfolio decision rather than a mechanistic defeat, but the strategic logic was shaped by mechanism. Oral small-molecule PD-L1 inhibition has repeatedly underperformed the expectations set by antibodies, and the field has thinned as sponsors concluded that the modality has not shown a clear advantage (Cancer Discovery commentary, 2023). The mechanistic reason is that small-molecule PD-L1 binders act largely by inducing PD-L1 dimerization, internalization, and degradation rather than by the durable, high-avidity surface occupancy that antibodies provide (Cancer Discovery, 2022). Translating that into consistent, antibody-comparable receptor coverage across a dosing interval is pharmacologically demanding, and the commercial case erodes when entrenched antibodies already cover the same indications. With five patients and no Part 2, INCB099280 generated no efficacy disappointment of its own. The program ended because the expected value of continuing did not clear Incyte's bar against a crowded antibody standard and a difficult oral pharmacology problem.

How to prevent this next time

Two quantitative tools would have sharpened the go or no-go before opening a combination cohort.

First, a competitive landscape red-team analysis. PD-L1 is among the most heavily worked targets in oncology, with 13 distinct mechanism-annotated molecules against CD274 in ChEMBL alone plus multiple approved antibodies (ChEMBL v34, CD274 CHEMBL3580522). A structured red-team would have scored the probability that an oral small molecule reaches antibody-comparable efficacy and pricing power against that field before resources were committed, and would have set a kill threshold tied to differentiation rather than to tolerability.

Second, a Bayesian predictive-probability framework applied to the portfolio decision. The predictive probability of success integrates the probability of a positive final result over the posterior for the treatment effect given interim data.

PP(success)=∫θ​P(final success∣θ,interim data)⋅π(θ∣interim data)dθ

A prior anchored on the weak historical base rate of oral checkpoint inhibitors, updated with the thin Part 1 data, would have produced a low predictive probability of a differentiated Part 2 result and a defensible early stop. Pre-specifying that quantity converts a late strategic cull into an explicit, earlier decision rule that spares patient and trial resources.

The single highest leverage change would have been to pre-specify a competitive differentiation threshold and a Bayesian predictive-probability gate at the start, so the oral PD-L1 program advanced or stopped on an explicit rule rather than a late portfolio sweep.

What this means for similar programs

The episode is a marker for an entire modality, not one molecule. Oral PD-L1 inhibitors crowded into the clinic and then thinned, and the surviving rationale must show pharmacology that antibodies cannot match, such as tissue penetration or intermittent dosing benefits, rather than oral convenience alone (Cancer Discovery commentary, 2023). Sponsors carrying small-molecule checkpoint binders should treat a heavily validated, antibody-dominated target as a reason for a higher differentiation bar, not a lower one. In the Claidex graph CD274 now carries a Mechanism Risk Score of 23 (green), low because this was a single early-phase strategic stop on a strongly evidenced target rather than an efficacy or safety failure (Claidex failure graph, 2026-06-06).

Open questions

Would INCB099280 have shown antibody-comparable activity in a larger Part 2, or was the oral pharmacology destined to fall short of durable receptor coverage? Did the narrow geographic footprint and the choice of axitinib as partner limit enrollment independent of the strategic decision? Can any oral PD-L1 inhibitor define a niche, for example combination dosing flexibility, that justifies continued investment against entrenched antibodies? The posted data cannot answer these.

Sources

1. • ClinicalTrials.gov, NCT05949632 (protocol, posted results): https://clinicaltrials.gov/study/NCT05949632 - Koblish HK et al. Characterization of INCB086550, a small-molecule PD-L1 inhibitor. Cancer Discovery 2022.- Wang T et al. Small-molecule PD-1/PD-L1 inhibitors that promote PD-L1 internalization and degradation. Journal of Medicinal Chemistry 2022.- Sun C et al. Novel small-molecule PD-L1 inhibitor inducing PD-L1 internalization. Journal of Medicinal Chemistry 2023.- Sullivan KMC et al. CCX559, an orally administered small-molecule PD-L1 inhibitor. PLoS One 2023.- Oral PD-L1 Inhibitors Crowd into the Clinic. Cancer Discovery 2023. - FierceBiotech. Incyte drops pair of PD-L1 drugs as part of second pipeline clear-out this year. 2025: https://www.fiercebiotech.com/biotech/incyte-drops-pair-pd-l1-drugs-part-second-pipeline-clear-out-year - BioPharma Dive. Incyte trims cancer drug pipeline in R&D refocus.
2. • ApexOnco. Incyte swings the axe on oral checkpoint inhibitors.
3. • Phase 1 Study of Oral PD-L1 Inhibitor INCB099280, ESMO-IO 2023 poster (Incyte). - Open Targets Platform, CD274 (ENSG00000120217), neoplasm (EFO_0000616): https://platform.opentargets.org/target/ENSG00000120217 - ChEMBL v34, CD274 target CHEMBL3580522 - openFDA FAERS, queried 2026-06-06.